Sugi Predict

Sugi Predict / Targets / HCN2

HCN2

Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 · Q9UL51 · HCN2 on Sugi Atlas →

78 patent compounds predicted against HCN2, 38 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL16511268 SCHEMBL16511268 0.60 1/20
SCHEMBL16511270 SCHEMBL16511270 0.58 1/20
SCHEMBL16510722 SCHEMBL16510722 0.57 1/20
SCHEMBL6633255 SCHEMBL6633255 0.56 1/20
SCHEMBL16510726 SCHEMBL16510726 0.56 1/20
SCHEMBL4354591 SCHEMBL4354591 0.51 1/20
SCHEMBL4358768 SCHEMBL4358768 0.51 1/20
SCHEMBL13706906 SCHEMBL13706906 0.51 1/20
SCHEMBL13706946 SCHEMBL13706946 0.50 1/20
SCHEMBL2469491 SCHEMBL2469491 0.48 1/20
SCHEMBL4374590 SCHEMBL4374590 0.48 1/20
SCHEMBL7398258 SCHEMBL7398258 0.48 1/20
SCHEMBL4374231 SCHEMBL4374231 0.47 1/20
SCHEMBL7362659 SCHEMBL7362659 0.46 1/20
SCHEMBL13570452 SCHEMBL13570452 0.45 1/20
SCHEMBL29003856 SCHEMBL29003856 0.45 1/20
SCHEMBL5666316 SCHEMBL5666316 0.44 1/20
SCHEMBL16511279 SCHEMBL16511279 0.44 1/20
SCHEMBL7397897 SCHEMBL7397897 0.44 1/20
SCHEMBL9283305 SCHEMBL9283305 0.43 1/20

Clinical trials — most relevant to HCN2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy PHASE3COMPLETED
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK) PHASE2/PHASE3RECRUITING
Role of Intralipid in Management of Organophosphorus Poisoning PHASE2/PHASE3WITHDRAWN
Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial PHASE2WITHDRAWN
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) PHASE1/PHASE2RECRUITING
StereoTactic Arrhythmia Radiotherapy in the NetherLands no. 2 PHASE2RECRUITING
High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy PHASE1COMPLETED
A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours PHASE1COMPLETED
Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese Males PHASE1COMPLETED
HNC: Human Neural Circuits Electrophysiology During Cognition PHASE1RECRUITING
Peripheral KV7 Activation for Pain Relief EARLY_PHASE1COMPLETED
The Use of Antiarrhythmic Drugs in Pediatrics nanUNKNOWN
Add-on HD Hf-tRNS Over Bilateral DLPFC for Treating Patients With Schizophrenia nanCOMPLETED
Neuronal Excitability of HCN1 Channel Mutations in Dravet Syndrome nanCOMPLETED
Measuring Single Neuron Activity in the Brain nanNOT_YET_RECRUITING
Characterization of Complex Pulse Shapes in Deep Brain Stimulation for Movement Disorders Using EEG and Local Field Potential Recordings nanCOMPLETED
Safety of Oral Resin for Treatment of Hyperkalemia in Chinese Patients With Renal Insufficiency nanCOMPLETED
MS Fatigue and tDCS on Fatigue in Multiple Sclerosis nanCOMPLETED
A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in China nanCOMPLETED
Mechanism and Dosimetry Exploration in TES Magnetic Resonance Current Mapping Methods nanCOMPLETED
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Does Atrial Fibrillation (AF) Termination Without Additional Ablation Influence Outcome? nanUNKNOWN
POTASSIUM-RICH SALT SUBSTITUTES IN KIDNEY TRANSPLANT RECIPIENTS nanNOT_YET_RECRUITING
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
Role of KATP Channel Loss in Type 2 Diabetes nanRECRUITING
The Energetic Origin of Neurodegeneration in MS nanCOMPLETED
Decoding Mechanisms of Pain Modulation nanCOMPLETED
ASD-specific Induced Pluripotent Stem Cells for Disease Modeling nanCOMPLETED
Boosting Exercise cApaCity With autOnomic Neuromodulation nanCOMPLETED
Intracranial EEG to Test How Noninvasive Stimulation Affects Hippocampal-dependent Memory nanENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a HCN2 binder may also engage these)

ProteinNameSimilarity
Q9JKA9 — 1.000 Q9JKA9 →
O88703 — 1.000 O88703 →
Q9JKA7 — 0.993 Q9JKA7 →
O88705 — 0.992 O88705 →
HCN4 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 0.990 landscape →
Q9TV66 — 0.989 Q9TV66 →
HCN3 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3 0.989 landscape →
Q9JKA8 — 0.988 Q9JKA8 →
O70507 — 0.988 O70507 →
HCN1 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 0.986 landscape →
Q9MZS1 — 0.986 Q9MZS1 →
O88704 — 0.982 O88704 →
Q9JKB0 — 0.981 Q9JKB0 →
Q9TUI4 — 0.976 Q9TUI4 →
KCNH3 Voltage-gated inwardly rectifying potassium channel KCNH3 0.976 landscape →
P50638 — 0.975 P50638 →
Q52PG9 — 0.974 Q52PG9 →
Q9R1T9 — 0.974 Q9R1T9 →
Q03717 — 0.973 Q03717 →
Q8WNY2 — 0.973 Q8WNY2 →
Q63099 — 0.973 Q63099 →
Q60603 — 0.973 Q60603 →
A6H8H5 — 0.972 A6H8H5 →
Q4ZHA6 — 0.972 Q4ZHA6 →
Q95167 — 0.972 Q95167 →
Q14003 — 0.972 Q14003 →
Q9Z0V1 — 0.971 Q9Z0V1 →
KCNH1 Voltage-gated delayed rectifier potassium channel KCNH1 0.971 landscape →
O18965 — 0.971 O18965 →
Q9NSA2 — 0.971 Q9NSA2 →